These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6160601)

  • 1. The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.
    Alberts DS; Chen HS; Chang SY; Peng YM
    Recent Results Cancer Res; 1980; 74():293-9. PubMed ID: 6160601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
    Alberts DS; Chen HG; Benz D; Mason NL
    Br J Cancer; 1981 Mar; 43(3):330-4. PubMed ID: 7225283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus.
    Crooke ST; Comis RL; Einhorn LH; Strong JE; Broughton A; Prestayko AW
    Cancer Treat Rep; 1977 Dec; 61(9):1631-6. PubMed ID: 74282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced changes in bleomycin elimination.
    Yee GC; Crom WR; Champion JE; Brodeur GM; Evans WE
    Cancer Treat Rep; 1983 Jun; 67(6):587-9. PubMed ID: 6190560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system.
    Greig NH; Momma S; Sweeney DJ; Smith QR; Rapoport SI
    Cancer Res; 1987 Mar; 47(6):1571-6. PubMed ID: 3815357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of food on oral melphalan absorption.
    Reece PA; Kotasek D; Morris RG; Dale BM; Sage RE
    Cancer Chemother Pharmacol; 1986; 16(2):194-7. PubMed ID: 3948305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy with melphalan.
    Howell SB; Pfeifle CE; Olshen RA
    Ann Intern Med; 1984 Jul; 101(1):14-8. PubMed ID: 6732077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of intravenous melphalan.
    Alberts DS; Chang SY; Chen HS; Moon TE; Evans TL; Furner RL; Himmelstein K; Gross JF
    Clin Pharmacol Ther; 1979 Jul; 26(1):73-80. PubMed ID: 445964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.
    Ardiet C; Tranchand B; Biron P; Rebattu P; Philip T
    Cancer Chemother Pharmacol; 1986; 16(3):300-5. PubMed ID: 3516430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of high-dose melphalan in children and adults.
    Gouyette A; Hartmann O; Pico JL
    Cancer Chemother Pharmacol; 1986; 16(2):184-9. PubMed ID: 3948304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.
    Nelson RL
    Med Pediatr Oncol; 1982; 10(2):115-27. PubMed ID: 7070351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy with cisplatin and melphalan.
    Piccart MJ; Abrams J; Dodion PF; Crespeigne N; Sculier JP; Pector JC; Finet C; Nouwijnck C; Bondue H; Atassi G
    J Natl Cancer Inst; 1988 Sep; 80(14):1118-24. PubMed ID: 3411624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
    Nagai K; Nogami S; Egusa H; Konishi H
    Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology of intraperitoneally administered bleomycin.
    Howell SB; Schiefer M; Andrews PA; Markman M; Abramson I
    J Clin Oncol; 1987 Dec; 5(12):2009-16. PubMed ID: 2445936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.
    Bosanquet AG; Gilby ED
    Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.
    Ginsberg S; Kirshner J; Reich S; Panasci L; Finkelstein T; Fandrich S; Fitzpatrick A; Shechtman L; Comis R
    Cancer Treat Rep; 1981; 65(5-6):477-83. PubMed ID: 6165472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.